Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:4.1.1.17 (
ornithine decarboxylase
)
6,351
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Our previous studies have shown that the overexpression of
ornithine decarboxylase
(
ODC
), the rate-limiting enzyme in polyamine biosynthesis, increases the enzymatic activity of the polyamine-responsive enzyme casein kinase 2 (CK2). Because CK2 is known to preferentially associate with the nuclear matrix in response to other trophic stimuli, we investigated the effects of
ODC
overexpression on CK2 localisation and on the CK2-mediated phosphorylation of a known CK2 substrate, the
nucleolar phosphoprotein B23
. Immunofluorescence analysis of CK2 and B23 in primary keratinocytes revealed that
ODC
overexpression resulted in the colocalisation of CK2 with B23 at the nucleolar borders.
ODC
overexpression also increased CK2 kinase activity 2-fold at the nuclear matrix, a response which could be abrogated by treatment of K6/
ODC
transgenic keratinocytes with the
ODC
inhibitor alpha-difluoromethylornithine (DFMO). Levels of B23 protein were also elevated in
ODC
-overexpressing cells compared to normal cells or transgenic cells treated with DFMO. This increase in protein level was neither due to an increase in steady-state mRNA levels, nor was it due to increased stability of B23 protein. Phosphorylation of B23 was also increased in
ODC
-overexpressing cells, and this increased phosphorylation could be blocked by treatment of the cells with the CK2 kinase inhibitors apigenin or 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB). These data suggest that B23 may be a downstream effector of polyamines via phosphorylation by the protein kinase CK2.
...
PMID:B23 is a downstream target of polyamine-modulated CK2. 1634 11